Vanguard Group Inc Halozyme Therapeutics, Inc. Transaction History

Vanguard Group Inc

$5.97 Trillion
Q2 2025

A detailed history of Vanguard Group Inc transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 12,245,602 shares of HALO stock, worth $787 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

12,245,602

Previous 12,831,503 4.57%

Holding current value

$787 Million

Previous $819 Million 22.2%

% of portfolio

0.01%

Previous 0.02%

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 11, 2025	SELL	$47.91 - $70.14 $28.1 Million - $41.1 Million	-585,901 Reduced 4.57%	12,245,602 $637 Million
Q1 2025 May 09, 2025	SELL	$47.74 - $65.16 $21.5 Million - $29.3 Million	-450,211 Reduced 3.39%	12,831,503 $819 Million
Q4 2024 Feb 11, 2025	BUY	$42.57 - $61.09 $16.5 Million - $23.6 Million	386,618 Added 3.0%	13,281,714 $635 Million
Q3 2024 Nov 13, 2024	BUY	$51.3 - $64.42 $699,578 - $878,495	13,637 Added 0.11%	12,895,096 $738 Million
Q2 2024 Aug 13, 2024	SELL	$37.81 - $52.4 $6.34 Million - $8.79 Million	-167,794 Reduced 1.29%	12,881,459 $674 Million
Q1 2024 May 10, 2024	SELL	$33.68 - $41.95 $7.08 Million - $8.82 Million	-210,261 Reduced 1.59%	13,049,253 $531 Million
Q4 2023 Feb 14, 2024	BUY	$33.32 - $42.1 $5.09 Million - $6.44 Million	152,870 Added 1.17%	13,259,514 $490 Million
Q3 2023 Nov 14, 2023	SELL	$36.46 - $44.03 $1.08 Million - $1.3 Million	-29,621 Reduced 0.23%	13,106,644 $501 Million
Q2 2023 Aug 14, 2023	SELL	$30.28 - $38.74 $11.6 Million - $14.9 Million	-383,374 Reduced 2.84%	13,136,265 $474 Million
Q1 2023 May 15, 2023	BUY	$32.86 - $55.7 $7.09 Million - $12 Million	215,792 Added 1.62%	13,519,639 $516 Million
Q4 2022 Feb 10, 2023	SELL	$40.06 - $59.44 $1.25 Million - $1.86 Million	-31,308 Reduced 0.23%	13,303,847 $757 Million
Q3 2022 Nov 14, 2022	BUY	$38.53 - $51.78 $1.48 Million - $1.99 Million	38,342 Added 0.29%	13,335,155 $527 Million
Q2 2022 Aug 12, 2022	BUY	$37.35 - $48.3 $1.75 Million - $2.26 Million	46,893 Added 0.35%	13,296,813 $585 Million
Q1 2022 May 13, 2022	SELL	$31.97 - $41.06 $7.86 Million - $10.1 Million	-245,993 Reduced 1.82%	13,249,920 $528 Million
Q4 2021 Feb 14, 2022	SELL	$31.82 - $40.75 $4.13 Million - $5.29 Million	-129,828 Reduced 0.95%	13,495,913 $543 Million
Q3 2021 Nov 12, 2021	SELL	$38.47 - $46.42 $483,298 - $583,174	-12,563 Reduced 0.09%	13,625,741 $554 Million
Q2 2021 Aug 13, 2021	BUY	$38.84 - $51.31 $530 Million - $700 Million	13,638,304 New	13,638,304 $619 Million

Others Institutions Holding HALO

# of Institutions

600

Shares Held

127M

Call Options Held

408K

Put Options Held

388K

View Full List

About HALOZYME THERAPEUTICS, INC.

Ticker HALO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 139,288,992
Market Cap $8.95B
Description
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...

More about HALO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Halozyme Therapeutics, Inc. Transaction History